Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2022
TOKYO, Japan and CAMBRIDGE, United Kingdom, May 13, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2022. The full report can be found by clicking here.
Chris Cargill, President and CEO of Sosei Heptares, commented: “Sosei Heptares is entering a new and exciting phase in 2022. We have made strong progress evolving our organic strategy and operational model and have put in place key pillars that significantly augment the existing talent and expertise at the Company. With a new leadership team and exciting collaborations underway with innovative partners such as Verily and Weatherden, we are building an agile, world-leading drug discovery and translational medicine capability in the UK to accelerate our shift toward becoming a multi-program, early clinical-stage business. Our goal is to take our best programs through Phase 1b/2a trials in patients, to cost effectively establish clinical proof-of-concept and support the delivery of much-needed medicines to patients as fast as possible.
“In addition to driving the above growth plan at our existing R&D business in the UK, we continue to seek expansion opportunities in the areas of drug discovery technology investments, securing products for patients in Japan, and assessing strategic acquisition opportunities.”
Operational Highlights for Q1 2022
Financial Highlights for Three-month period ended 31 March 2022
*Convenience conversion to US$ at the following rates: YTD 2022: 1US$ =116.19 JPY; YTD 2021: 1US$ =106.09 JPY, 31 Dec 2021: 1US$ = 115.07 JPY; 31 Mar 2022: 1US$ = 121.83 JPY
About Sosei Heptares
We have established partnerships with some of the world’s leading pharmaceutical companies and multiple emerging technology companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Neurocrine Biosciences, Novartis, Pfizer, Takeda and Verily. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.
“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.
Sosei Heptares – Media and Investor Relations
MEDiSTRAVA Consulting (for International Media)